WO2018226098A3 - Methods for typing neurological disorders and cancer, and devices for use therein - Google Patents

Methods for typing neurological disorders and cancer, and devices for use therein Download PDF

Info

Publication number
WO2018226098A3
WO2018226098A3 PCT/NL2018/050370 NL2018050370W WO2018226098A3 WO 2018226098 A3 WO2018226098 A3 WO 2018226098A3 NL 2018050370 W NL2018050370 W NL 2018050370W WO 2018226098 A3 WO2018226098 A3 WO 2018226098A3
Authority
WO
WIPO (PCT)
Prior art keywords
typing
cancer
methods
devices
sample
Prior art date
Application number
PCT/NL2018/050370
Other languages
French (fr)
Other versions
WO2018226098A2 (en
Inventor
Maarten TITULAER
Original Assignee
Erasmus University Medical Center Rotterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erasmus University Medical Center Rotterdam filed Critical Erasmus University Medical Center Rotterdam
Publication of WO2018226098A2 publication Critical patent/WO2018226098A2/en
Publication of WO2018226098A3 publication Critical patent/WO2018226098A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to a method for detecting antibodies against a GABAB receptor in a sample of a subject, comprising the steps of providing a sample from a subject, wherein said sample comprises, or is suspected of comprising, antibodies against a GABAB receptor; providing a composition comprising a GABAB receptor and a KCTD protein; contacting said sample with said composition, and performing an immunoassay to determine the presence of an antibody against a GABAB receptor in said sample.
PCT/NL2018/050370 2017-06-07 2018-06-07 Methods for typing neurological disorders and cancer, and devices for use therein WO2018226098A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17174809 2017-06-07
EP17174809.8 2017-06-07

Publications (2)

Publication Number Publication Date
WO2018226098A2 WO2018226098A2 (en) 2018-12-13
WO2018226098A3 true WO2018226098A3 (en) 2019-01-17

Family

ID=59077813

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2018/050370 WO2018226098A2 (en) 2017-06-07 2018-06-07 Methods for typing neurological disorders and cancer, and devices for use therein

Country Status (1)

Country Link
WO (1) WO2018226098A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022058309A1 (en) * 2020-09-15 2022-03-24 Universite Claude Bernard Lyon 1 Anti-argonaute protein autoantibodies as biomarkers of autoimmune neurological diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041433A1 (en) * 2009-09-29 2011-04-07 The Trustees Of The University Of Pennsylvania Methods for diagnosing and treating encephalitis or epilepsy
EP2806274A1 (en) * 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Lung cancer diagnostic method and means

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041433A1 (en) * 2009-09-29 2011-04-07 The Trustees Of The University Of Pennsylvania Methods for diagnosing and treating encephalitis or epilepsy
EP2806274A1 (en) * 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Lung cancer diagnostic method and means

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HASEGAWA TADASHI ET AL: "Use of potassium channel tetramerization domain-containing 12 as a biomarker for diagnosis and prognosis of gastrointestinal stromal tumor", HUMAN PATHOLOGY, SAUNDERS, PHILADELPHIA, PA, US, vol. 44, no. 7, 3 January 2013 (2013-01-03), pages 1271 - 1277, XP028569770, ISSN: 0046-8177, DOI: 10.1016/J.HUMPATH.2012.10.013 *
METZ MICHAELA: "Characterization of a Novel Familyof GABAB Receptor Interacting Proteins- KCTD8, 12, 12b, and 16", 8 December 2009 (2009-12-08), Universität Basel, pages 1 - 127, XP002786407, Retrieved from the Internet <URL:https://edoc.unibas.ch/1095/1/20091218E-diss_Michaela_Metz.pdf> [retrieved on 20181109] *
T. OHKAWA ET AL: "Identification and Characterization of GABAA Receptor Autoantibodies in Autoimmune Encephalitis", JOURNAL OF NEUROSCIENCE, vol. 34, no. 24, 11 June 2014 (2014-06-11), US, pages 8151 - 8163, XP055415725, ISSN: 0270-6474, DOI: 10.1523/JNEUROSCI.4415-13.2014 *
TURECEK ROSTISLAV ET AL: "Auxiliary GABABReceptor Subunits Uncouple G Protein [beta][gamma] Subunits from Effector Channels to Induce Desensi", NEURON, vol. 82, no. 5, 2014, pages 1032 - 1044, XP028848616, ISSN: 0896-6273, DOI: 10.1016/J.NEURON.2014.04.015 *
VAN COEVORDEN-HAMEETE ET AL: "Autoantibodies to KCTD16 mark the presence of a tumor in patients with GABAb receptor encephalitis", EUROPEAN JOURNAL OF NEUROLOGY, vol. 25, no. Supplement 2, EPR3135, 16 June 2018 (2018-06-16), 4th Congress of the European-Academy-of-Neurology (EAN); Lisbon, PORTUGAL; June 16 -19, 2018, pages 553, XP002786408 *
XINNONG JIANG: "GABA b receptor complex as a potential target for tumor therapy", JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1 January 2012 (2012-01-01), XP055413726, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351242/pdf/10.1369_0022155412438105.pdf> [retrieved on 20171009] *
ZHEPENG LIU ET AL: "The KCTD family of proteins: structure, function, disease relevance", CELL & BIOSCIENCE, BIOMED CENTRAL LTD, LONDON, UK, vol. 3, no. 1, 24 November 2013 (2013-11-24), pages 45, XP021173818, ISSN: 2045-3701, DOI: 10.1186/2045-3701-3-45 *

Also Published As

Publication number Publication date
WO2018226098A2 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
MX2020009021A (en) Assays for detecting the presence or amount of an anti-drug antibody.
NZ706187A (en) Assays for the detection of anti-tnf drugs and autoantibodies
MX2020010387A (en) Methods for detecting and quantifying fgf21.
NZ609363A (en) Methods for determining anti-drug antibody isotypes
ECSP088081A (en) DETECTION OF AN ANCIENT DIANA INDEPENDENTLY FROM THE PRESENCE OR ABSENCE OF A CORRESPONDING THERAPEUTIC ANTIBODY
WO2017194613A3 (en) Method, array and use thereof
MX2019008911A (en) Methods, arrays and uses thereof.
MX2020000186A (en) Assays for assessing neutralizing antibodies levels in subjects treated with a biological drug and uses thereof in personalized medicine.
AU2018274704A1 (en) Assay for plasma cell associated disease
EA202190237A1 (en) METHODS TO REDUCE INTERFERING EFFECTS OF A DRUG TARGET IN IMMUNOLOGICAL ANALYSIS FOR DRUG ANTIBODIES (ADA)
WO2015148609A3 (en) Immunoassays using colloidal crystals
MX369610B (en) Methods, devices, and systems for sample analysis.
WO2018167141A3 (en) Target detection using a monovalent antibody
EP4300101A3 (en) Antigenic peptides and uses thereof for diagnosing and treating autism
MX2019000592A (en) Liquid analytical reagent dispensing apparatus and analytical kits and methods of use related thereto.
EA201400571A1 (en) SPECIFIC TO TRANSRESVEROTROL ANTIBODIES AND THEIR APPLICATION
WO2014161910A3 (en) Methods and arrays for use in biomarker detection for prostate cancer
WO2018226098A3 (en) Methods for typing neurological disorders and cancer, and devices for use therein
EA201692071A1 (en) IMMUNOANALYSIS AND ANTIBODIES FOR CHROMOGRANINE A DETECTION
EP4253950A3 (en) Ce-western applications for antibody development
MX2022013738A (en) Neutralizing antibody assay for therapeutic proteins.
MX2016007148A (en) A-glucan assay methods.
GB2550707A (en) Determining the hydrocarbon plus fraction of a sample separated by gas chromatography
MY194325A (en) Test object detection method, and immunoassay instrument and monoclonal antibody for same
MX2018015047A (en) Method for the detection of an IgM antibody specific for a flavivirus in a sample.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18732504

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18732504

Country of ref document: EP

Kind code of ref document: A2